NCT01635907View on ClinicalTrials.gov

Dovitinib in Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

April 11, 2016

Conditions
Advanced Metastatic ParagangliomaAdvanced Metastatic PheochromocytomaRecurrent ParagangliomaRecurrent PheochromocytomaUnresectable ParagangliomaUnresectable Pheochromocytoma
Interventions
DRUG

Dovitinib

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01635907 - Dovitinib in Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter